All Eli Lilly and Company articles – Page 2
-
NewsPharma cautious about rushing towards direct-to-consumer drug sales
Disruption to traditional distribution channels is anticipated to hinder widespread adoption of the channel.
-
News
Lilly to sell off Branchburg site as its US manufacturing plans take shape
The pharma company’s digital innovation efforts also progress with the opening of a new Hyderabad facility.
-
NewsExtension trial demonstrates long-term benefit for Lilly Alzheimer's drug
The new findings support a limited duration dosing approach and highlight the consistent safety profile for Eli Lilly’s antibody drug.
-
ArticleWhat will shape the Pharma landscape in Q3 2025?
Upcoming drug approvals and clinical progress will be pivotal during the third quarter of the year, says GlobalData.
-
NewsEli Lilly genetic medicine acquisition to address cardiovascular risk
The agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that provide a long-term reduction of cardiovascular risk factors.
-
NewsR&D and tech innovation boosting biopharmaceutical market to 2030
Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports.
-
NewsNew Eli Lilly acquisition to progress potential next-generation pain treatment
The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.
-
NewsEli Lilly to lead oligonucleotide therapy development in new collaboration
The partnership between Eli Lilly and Company and Creyon Bio will focus on producing safer, more effective RNA-targeted oligonucleotide therapies with the use of AI technology.
-
NewsEli Lilly releases topline data for new oral GLP-1
Subject to regulatory approval, the small molecule drug could provide a new treatment option for diabetes and obesity, Eli Lilly’s new data suggests.
-
NewsLilly IBD biologic receives expanded US approval
The drug is the first biologic in over 15 years to have disclosed two-year Phase III efficacy data in Crohn's disease at the time of approval.
-
ArticlePotential blockbuster drugs to watch in 2025
Eleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
-
NewsEli Lilly collaboration to accelerate biotech manufacturing
The partnership will provide biotech companies with accelerated access to clinical development capabilities, including drug development and analytical services.
-
ArticleDeveloping donanemab - balancing cost versus benefit
This article summarises recent regulatory developments surrounding the Alzheimer’s treatment donanemab and considers the future therapeutic market for this disease.
-
NewsEli Lilly secures MHRA authorisation for Alzheimer's treatment
Authorisation in Great Britain means eligible Alzheimer's patients can access the treatment, which is part of a new class of amyloid targeting therapies.
-
NewsEli Lilly appoints Chief AI Officer
The new appointee will create AI and machine learning solutions to support Eli Lilly’s medicines for patients globally.
-
NewsLilly $1.8 billion investment to bolster Irish manufacturing
The expansion is planned to support production of Eli Lilly and Company’s medicines for diabetes, obesity and Alzheimer's and both sites will harness advanced technology and sustainability capabilities.
-
ArticleHarnessing the GLP-1R medicine wave
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
-
NewsFirst-of-a-kind trial holds promise for obesity and pre-diabetes treatment
The treatment reduces the risk of progression to type 2 diabetes and supports long-term maintenance of weight loss in adults with pre-diabetes and obesity or who are overweight, data indicates.
-
ArticleAlzheimer’s drug development roundup – July 2024
From exciting data on cell therapy and monoclonal antibodies, through to new regulatory developments, this article summarises some of the key developments within the Alzheimer’s therapeutic landscape over July.
-
NewsFrom biologics to small molecules – the shift in biopharma’s revenue growth
Biopharma companies that experienced strong revenue growth due to COVID-19 drug sales have been overtaken by companies that developed obesity drugs in 2023, GlobalData suggests.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page